FindTrial
Sign In

Study on the diagnosis and treatment integration of lung cancer by perfluorocarbon nanoprobe via respiratory tract

Study on the diagnosis and treatment integration of lung cancer by perfluorocarbon nanoprobe via respiratory tract

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR-ONC-17014132
Enrollment
Unknown
Registered
2017-12-25
Start date
2018-12-01
Completion date
Unknown
Last updated
2018-01-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lung Cancer

Interventions

PFC:Respiratory delivery

Sponsors

The 4th Affiliated Hospital of Harbin Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Male or female aged 18 to 80 years; 2. lung cancer; 3. voluntary participate the clinical research and sign on the informed consent.

Exclusion criteria

Exclusion criteria: 1. patients with other primary malignancies; 2. Patients with serious diseases and severe dysfunction of the heart, liver, kidney; 3. pregnant or lactating women; 4. Patients with mental or cognitive impairment which influence the quality of life in this study; 5. Patients who are participating in other clinical trials; 6. Patients with poor compliance or other situations the researchers believe that is not eligible for inclusion.

Design outcomes

Primary

MeasureTime frame
Tumor size;Clinical symptoms;Tumor markers;—

Countries

China

Contacts

Public ContactShen Baozhong

Harbin Medical University

shenbzh@vip.sina.com+86 0451-82576508

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026